37 results
Page 2 of 2
6-K
EX-99.1
rue7xdnunaebq6
29 Dec 20
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
7:30am
424B5
9p9jfwos ipbxj8lx
23 Sep 20
Prospectus supplement for primary offering
8:06am
424B5
2mwp4d5a
16 Sep 20
Prospectus supplement for primary offering
7:24am
6-K
EX-99.1
zkcwqe
11 Sep 20
Zai Lab Limited Supplemental and Updated Disclosures
8:09am
6-K
EX-99.1
644 uwwged0porjzgksg
17 Aug 20
Zai Lab Appoints F. Ty Edmondson as Chief Legal Officer
7:35am
6-K
EX-99.1
f2n6q
8 Apr 20
Zai Lab obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau
6:03am
424B2
x5pt0jy5azdy9sjttg
24 Jan 20
Prospectus for primary offering
7:24am
424B5
fbe2 y2bmk5fa7zd
21 Jan 20
Prospectus supplement for primary offering
5:31pm
6-K
EX-99.1
2qitjkm7t
14 Jan 20
Zai Lab Appoints Lonnie Moulder to Board of Directors
7:30am
424B2
w3pw9 f15tzyiz
6 May 19
Prospectus for primary offering
6:04am
424B5
qqfhegh
1 May 19
Prospectus supplement for primary offering
5:26pm
F-3ASR
vu68y6otcxi7hcsbt0
29 Mar 19
Automatic shelf registration (foreign)
5:13pm
424B4
87rp2y6ics78d
7 Sep 18
Prospectus supplement with pricing info
12:00am
20-F
q6k61sqlc6lkb8dbcnwa
30 Apr 18
Annual report (foreign)
9:07am
6-K
EX-99.1
y6y6acns6v7jg3y36spw
25 Apr 18
Global Strategic Development Collaboration for ETX2514
12:00am